LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

Kodu・Aktsiate loetelu・AnaptysBio Inc

AnaptysBio Inc

Avatud

SektorTervishoid

67.64 -2.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

66.88

Max

69.61

Põhinäitajad
By Trading Economics
Sissetulek	35M 50M
Müük	32M 108M
Kasumimarginaal	45.833
Töötajad	104
EBITDA	29M 68M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+12.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	15. mai 2026

Turustatistika
By TradingEconomics
Turukapital	495M 2B
Eelmine avamishind	69.81
Eelmine sulgemishind	67.64

Uudiste sentiment

By Acuity

42%

58%

119 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

19.25 / 21.135 Toetus ja vastupanu

AnaptysBio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. mai 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10. mai 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10. mai 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10. mai 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Elevra Lithium: Expects Deal to Close in 1Q FY27

10. mai 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10. mai 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10. mai 2026, 10:21 UTC

Tulu

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9. mai 2026, 06:05 UTC

Tulu

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8. mai 2026, 23:55 UTC

Tulu

Review & Preview: Still Going Strong -- Barrons.com

8. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. mai 2026, 20:49 UTC

Tulu

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8. mai 2026, 20:25 UTC

Tulu

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. mai 2026, 19:43 UTC

Tulu

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8. mai 2026, 19:43 UTC

Tulu

Cencosud 1Q Net $115M

8. mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8. mai 2026, 19:18 UTC

Tulu

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8. mai 2026, 19:16 UTC

Tulu

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. mai 2026, 19:08 UTC

Tulu

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. mai 2026, 19:05 UTC

Tulu

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8. mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8. mai 2026, 18:51 UTC

Tulu

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8. mai 2026, 18:49 UTC

Tulu

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. mai 2026, 18:41 UTC

Tulu

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8. mai 2026, 17:14 UTC

Tulu

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8. mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

AnaptysBio Inc Prognoos

Hinnasiht

By TipRanks

12.89% tõus

12 kuu keskmine prognoos

Keskmine 78.27 USD 12.89%

Kõrge 140 USD

Madal 50 USD

Põhineb 11 Wall Streeti analüütiku instrumendi AnaptysBio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi AnaptysBio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

19.25 / 21.135Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

119 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.